KR20080011677A - 신규 ｍｃｈｒ1 길항제 및 그의 ｍｃｈｒ1 매개된 상태 및장애의 치료를 위한 용도 - Google Patents
신규 ｍｃｈｒ1 길항제 및 그의 ｍｃｈｒ1 매개된 상태 및장애의 치료를 위한 용도 Download PDFInfo
- Publication number
- KR20080011677A KR20080011677A KR1020077027793A KR20077027793A KR20080011677A KR 20080011677 A KR20080011677 A KR 20080011677A KR 1020077027793 A KR1020077027793 A KR 1020077027793A KR 20077027793 A KR20077027793 A KR 20077027793A KR 20080011677 A KR20080011677 A KR 20080011677A
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- yloxy
- benzyl
- piperidin
- benzamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000005557 antagonist Substances 0.000 title description 6
- 102100027375 Melanin-concentrating hormone receptor 1 Human genes 0.000 title description 5
- 230000001404 mediated effect Effects 0.000 title description 5
- 101000581402 Homo sapiens Melanin-concentrating hormone receptor 1 Proteins 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 132
- 238000000034 method Methods 0.000 claims abstract description 27
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 44
- -1 oct-3-yloxy Chemical group 0.000 claims description 44
- 208000019901 Anxiety disease Diseases 0.000 claims description 30
- 230000036506 anxiety Effects 0.000 claims description 23
- 208000035475 disorder Diseases 0.000 claims description 23
- 201000010099 disease Diseases 0.000 claims description 21
- 125000000217 alkyl group Chemical group 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- 208000019906 panic disease Diseases 0.000 claims description 18
- 230000002265 prevention Effects 0.000 claims description 18
- 101150104680 MCH1 gene Proteins 0.000 claims description 16
- 101100382379 Rattus norvegicus Cap1 gene Proteins 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 15
- 208000008589 Obesity Diseases 0.000 claims description 14
- 235000020824 obesity Nutrition 0.000 claims description 14
- 208000002193 Pain Diseases 0.000 claims description 12
- KAAHTYMQPGOFRE-UHFFFAOYSA-N n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]-4-[4-(trifluoromethoxy)phenyl]benzamide Chemical compound C1CN(C)CCC1OC1=CC=CC(CNC(=O)C=2C=CC(=CC=2)C=2C=CC(OC(F)(F)F)=CC=2)=C1 KAAHTYMQPGOFRE-UHFFFAOYSA-N 0.000 claims description 11
- 208000020016 psychiatric disease Diseases 0.000 claims description 11
- 208000020925 Bipolar disease Diseases 0.000 claims description 10
- 208000030814 Eating disease Diseases 0.000 claims description 10
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 10
- 208000012902 Nervous system disease Diseases 0.000 claims description 10
- 235000014632 disordered eating Nutrition 0.000 claims description 10
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 9
- 206010033664 Panic attack Diseases 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 206010027940 Mood altered Diseases 0.000 claims description 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
- 230000007510 mood change Effects 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 230000009286 beneficial effect Effects 0.000 claims description 6
- MRBZBRGOCVOJJT-UHFFFAOYSA-N n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]-1-(4-phenoxyphenyl)methanamine Chemical compound C1CN(C)CCC1OC1=CC=CC(CNCC=2C=CC(OC=3C=CC=CC=3)=CC=2)=C1 MRBZBRGOCVOJJT-UHFFFAOYSA-N 0.000 claims description 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 125000004434 sulfur atom Chemical group 0.000 claims description 6
- FDPKGXQCDURRBM-UHFFFAOYSA-N 4-(4-methoxyphenyl)benzoic acid Chemical compound C1=CC(OC)=CC=C1C1=CC=C(C(O)=O)C=C1 FDPKGXQCDURRBM-UHFFFAOYSA-N 0.000 claims description 5
- NNJMFJSKMRYHSR-UHFFFAOYSA-N 4-phenylbenzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=CC=C1 NNJMFJSKMRYHSR-UHFFFAOYSA-N 0.000 claims description 5
- 125000004429 atom Chemical group 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 5
- UAABKJIRDJPISQ-UHFFFAOYSA-N n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]-4-phenoxybenzamide Chemical compound C1CN(C)CCC1OC1=CC=CC(CNC(=O)C=2C=CC(OC=3C=CC=CC=3)=CC=2)=C1 UAABKJIRDJPISQ-UHFFFAOYSA-N 0.000 claims description 5
- ZXQYZHKJAOBIOV-UHFFFAOYSA-N 4-phenoxy-n-[(3-piperidin-4-yloxyphenyl)methyl]benzamide Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1C(=O)NCC(C=1)=CC=CC=1OC1CCNCC1 ZXQYZHKJAOBIOV-UHFFFAOYSA-N 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- AFMXBORFJZKSOK-UHFFFAOYSA-N n-[[3-(1-ethylpiperidin-4-yl)oxyphenyl]methyl]-4-phenoxybenzamide Chemical compound C1CN(CC)CCC1OC1=CC=CC(CNC(=O)C=2C=CC(OC=3C=CC=CC=3)=CC=2)=C1 AFMXBORFJZKSOK-UHFFFAOYSA-N 0.000 claims description 4
- BBUSGCSBLGJHHL-UHFFFAOYSA-N n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]-3-phenoxybenzamide Chemical compound C1CN(C)CCC1OC1=CC=CC(CNC(=O)C=2C=C(OC=3C=CC=CC=3)C=CC=2)=C1 BBUSGCSBLGJHHL-UHFFFAOYSA-N 0.000 claims description 4
- 239000002243 precursor Substances 0.000 claims description 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 3
- BVJKDGKGYCBMNN-UHFFFAOYSA-N 4-(4-methoxyphenyl)-n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]benzamide Chemical compound C1=CC(OC)=CC=C1C1=CC=C(C(=O)NCC=2C=C(OC3CCN(C)CC3)C=CC=2)C=C1 BVJKDGKGYCBMNN-UHFFFAOYSA-N 0.000 claims description 3
- CREKGPKHHFBOBC-UHFFFAOYSA-N 4-(4-methoxyphenyl)-n-methyl-n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]benzamide Chemical compound C1=CC(OC)=CC=C1C1=CC=C(C(=O)N(C)CC=2C=C(OC3CCN(C)CC3)C=CC=2)C=C1 CREKGPKHHFBOBC-UHFFFAOYSA-N 0.000 claims description 3
- PJDYFSZUHGVJRM-UHFFFAOYSA-N 4-benzyl-n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]benzamide Chemical compound C1CN(C)CCC1OC1=CC=CC(CNC(=O)C=2C=CC(CC=3C=CC=CC=3)=CC=2)=C1 PJDYFSZUHGVJRM-UHFFFAOYSA-N 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 125000001072 heteroaryl group Chemical group 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 3
- YVEQXBUNXFOMPK-UHFFFAOYSA-N n-[[3-(1-benzylpiperidin-4-yl)oxyphenyl]methyl]-4-phenoxybenzamide Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1C(=O)NCC(C=1)=CC=CC=1OC(CC1)CCN1CC1=CC=CC=C1 YVEQXBUNXFOMPK-UHFFFAOYSA-N 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- FICBTMWNFWJNQL-UHFFFAOYSA-N 1-(4-chlorophenyl)-n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]methanamine Chemical compound C1CN(C)CCC1OC1=CC=CC(CNCC=2C=CC(Cl)=CC=2)=C1 FICBTMWNFWJNQL-UHFFFAOYSA-N 0.000 claims description 2
- OAGWHNQUCXPGIV-UHFFFAOYSA-N 3-[4-(dimethylamino)phenyl]-n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]benzamide Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=CC(C(=O)NCC=2C=C(OC3CCN(C)CC3)C=CC=2)=C1 OAGWHNQUCXPGIV-UHFFFAOYSA-N 0.000 claims description 2
- LXWNTLBMNCXRQN-UHFFFAOYSA-N 4'-fluoro-1,1'-biphenyl-4-carboxylic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=C(F)C=C1 LXWNTLBMNCXRQN-UHFFFAOYSA-N 0.000 claims description 2
- VXMLQXJQYHWFNO-UHFFFAOYSA-N 4-(3-chlorophenyl)-n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]benzamide Chemical compound C1CN(C)CCC1OC1=CC=CC(CNC(=O)C=2C=CC(=CC=2)C=2C=C(Cl)C=CC=2)=C1 VXMLQXJQYHWFNO-UHFFFAOYSA-N 0.000 claims description 2
- HIZAKWSGPSDQAZ-UHFFFAOYSA-N 4-(4-chlorophenyl)-n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]benzamide Chemical compound C1CN(C)CCC1OC1=CC=CC(CNC(=O)C=2C=CC(=CC=2)C=2C=CC(Cl)=CC=2)=C1 HIZAKWSGPSDQAZ-UHFFFAOYSA-N 0.000 claims description 2
- CTZYDPNPAYTPAJ-UHFFFAOYSA-N 4-(4-fluoro-3-methylphenyl)-n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]benzamide Chemical compound C1CN(C)CCC1OC1=CC=CC(CNC(=O)C=2C=CC(=CC=2)C=2C=C(C)C(F)=CC=2)=C1 CTZYDPNPAYTPAJ-UHFFFAOYSA-N 0.000 claims description 2
- QTCDZQVGZSUQBS-UHFFFAOYSA-N 4-(4-fluorophenyl)-n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]benzamide Chemical compound C1CN(C)CCC1OC1=CC=CC(CNC(=O)C=2C=CC(=CC=2)C=2C=CC(F)=CC=2)=C1 QTCDZQVGZSUQBS-UHFFFAOYSA-N 0.000 claims description 2
- SPQOKMMLLGTJJL-UHFFFAOYSA-N 4-(4-methylphenyl)-n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]benzamide Chemical compound C1CN(C)CCC1OC1=CC=CC(CNC(=O)C=2C=CC(=CC=2)C=2C=CC(C)=CC=2)=C1 SPQOKMMLLGTJJL-UHFFFAOYSA-N 0.000 claims description 2
- YLRKXJUMQVWTOI-UHFFFAOYSA-N 4-cyclohexyl-n-methyl-n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]benzamide Chemical compound C=1C=C(C2CCCCC2)C=CC=1C(=O)N(C)CC(C=1)=CC=CC=1OC1CCN(C)CC1 YLRKXJUMQVWTOI-UHFFFAOYSA-N 0.000 claims description 2
- RISSPRUZBRTULC-UHFFFAOYSA-N 4-phenoxy-n-[[3-(1-propylpiperidin-4-yl)oxyphenyl]methyl]benzamide Chemical compound C1CN(CCC)CCC1OC1=CC=CC(CNC(=O)C=2C=CC(OC=3C=CC=CC=3)=CC=2)=C1 RISSPRUZBRTULC-UHFFFAOYSA-N 0.000 claims description 2
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims description 2
- 208000029364 generalized anxiety disease Diseases 0.000 claims description 2
- KQQFOGNNTZAYAL-UHFFFAOYSA-N n-(1,3-benzodioxol-5-ylmethyl)-1-[3-(1-methylpiperidin-4-yl)oxyphenyl]methanamine Chemical compound C1CN(C)CCC1OC1=CC=CC(CNCC=2C=C3OCOC3=CC=2)=C1 KQQFOGNNTZAYAL-UHFFFAOYSA-N 0.000 claims description 2
- PQANLFYFLBRNSR-UHFFFAOYSA-N n-[[3-(1-cyclopropylpiperidin-4-yl)oxyphenyl]methyl]-4-phenoxybenzamide Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1C(=O)NCC(C=1)=CC=CC=1OC(CC1)CCN1C1CC1 PQANLFYFLBRNSR-UHFFFAOYSA-N 0.000 claims description 2
- QAIVOSFJXAMSDU-UHFFFAOYSA-N n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]-1-(4-phenylphenyl)methanamine Chemical compound C1CN(C)CCC1OC1=CC=CC(CNCC=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 QAIVOSFJXAMSDU-UHFFFAOYSA-N 0.000 claims description 2
- RAXRPWHEVIYGCB-UHFFFAOYSA-N n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]-1-(4-propan-2-ylphenyl)methanamine Chemical compound C1=CC(C(C)C)=CC=C1CNCC1=CC=CC(OC2CCN(C)CC2)=C1 RAXRPWHEVIYGCB-UHFFFAOYSA-N 0.000 claims description 2
- KSKVZHOHVWXVIP-UHFFFAOYSA-N n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]-4-(4-methylsulfonylphenyl)benzamide Chemical compound C1CN(C)CCC1OC1=CC=CC(CNC(=O)C=2C=CC(=CC=2)C=2C=CC(=CC=2)S(C)(=O)=O)=C1 KSKVZHOHVWXVIP-UHFFFAOYSA-N 0.000 claims description 2
- VMSMZDPNNGYOLL-UHFFFAOYSA-N n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]-4-phenylbenzamide Chemical compound C1CN(C)CCC1OC1=CC=CC(CNC(=O)C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 VMSMZDPNNGYOLL-UHFFFAOYSA-N 0.000 claims description 2
- YNQVBDCUPBKVPE-UHFFFAOYSA-N n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]-4-phenylmethoxybenzamide Chemical compound C1CN(C)CCC1OC1=CC=CC(CNC(=O)C=2C=CC(OCC=3C=CC=CC=3)=CC=2)=C1 YNQVBDCUPBKVPE-UHFFFAOYSA-N 0.000 claims description 2
- IADYROZDLAWMHG-UHFFFAOYSA-N n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]-4-thiophen-3-ylbenzamide Chemical compound C1CN(C)CCC1OC1=CC=CC(CNC(=O)C=2C=CC(=CC=2)C2=CSC=C2)=C1 IADYROZDLAWMHG-UHFFFAOYSA-N 0.000 claims description 2
- NQQFNYNBNBXFNX-UHFFFAOYSA-N n-[[3-[(4-methylpiperazin-1-yl)methyl]phenyl]methyl]-4-phenoxybenzamide Chemical compound C1CN(C)CCN1CC1=CC=CC(CNC(=O)C=2C=CC(OC=3C=CC=CC=3)=CC=2)=C1 NQQFNYNBNBXFNX-UHFFFAOYSA-N 0.000 claims description 2
- IGLJXAOHZMBCMN-UHFFFAOYSA-N n-[[3-[1-(2,2-dimethylpropyl)piperidin-4-yl]oxyphenyl]methyl]-4-phenoxybenzamide Chemical compound C1CN(CC(C)(C)C)CCC1OC1=CC=CC(CNC(=O)C=2C=CC(OC=3C=CC=CC=3)=CC=2)=C1 IGLJXAOHZMBCMN-UHFFFAOYSA-N 0.000 claims description 2
- SZDZVNAICFHQQD-UHFFFAOYSA-N n-[[3-[1-(oxolan-3-yl)piperidin-4-yl]oxyphenyl]methyl]-4-phenoxybenzamide Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1C(=O)NCC(C=1)=CC=CC=1OC(CC1)CCN1C1CCOC1 SZDZVNAICFHQQD-UHFFFAOYSA-N 0.000 claims description 2
- DCOVPKWLIJKMTM-UHFFFAOYSA-N n-ethyl-n-[[3-(1-ethylpiperidin-4-yl)oxyphenyl]methyl]-4-phenoxybenzamide Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1C(=O)N(CC)CC(C=1)=CC=CC=1OC1CCN(CC)CC1 DCOVPKWLIJKMTM-UHFFFAOYSA-N 0.000 claims description 2
- CVMJFDVTAZFJLW-UHFFFAOYSA-N n-methyl-n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]-1-(4-phenoxyphenyl)methanamine Chemical compound C=1C=CC(OC2CCN(C)CC2)=CC=1CN(C)CC(C=C1)=CC=C1OC1=CC=CC=C1 CVMJFDVTAZFJLW-UHFFFAOYSA-N 0.000 claims description 2
- PKMRIBLWFLQQTE-UHFFFAOYSA-N n-methyl-n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]-4-phenylbenzamide Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1C(=O)N(C)CC(C=1)=CC=CC=1OC1CCN(C)CC1 PKMRIBLWFLQQTE-UHFFFAOYSA-N 0.000 claims description 2
- 206010027951 Mood swings Diseases 0.000 claims 1
- GBQVRCQAGWZRJP-UHFFFAOYSA-N n-methyl-n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]-4-phenoxybenzamide Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1C(=O)N(C)CC(C=1)=CC=CC=1OC1CCN(C)CC1 GBQVRCQAGWZRJP-UHFFFAOYSA-N 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- 239000007787 solid Substances 0.000 description 41
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- 101800002739 Melanin-concentrating hormone Proteins 0.000 description 18
- 102400001132 Melanin-concentrating hormone Human genes 0.000 description 18
- ORRDHOMWDPJSNL-UHFFFAOYSA-N melanin concentrating hormone Chemical compound N1C(=O)C(C(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(NC(=O)C(N)CC(O)=O)C(C)O)CCSC)CSSCC(C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)C)C(O)=O)NC(=O)C2CCCN2C(=O)C(CCCNC(N)=N)NC(=O)C1CC1=CC=C(O)C=C1 ORRDHOMWDPJSNL-UHFFFAOYSA-N 0.000 description 18
- 102000005962 receptors Human genes 0.000 description 18
- 108020003175 receptors Proteins 0.000 description 18
- 239000000203 mixture Substances 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 229910004298 SiO 2 Inorganic materials 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- 229910052722 tritium Inorganic materials 0.000 description 9
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 8
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 102000029828 Melanin-concentrating hormone receptor Human genes 0.000 description 7
- 108010047068 Melanin-concentrating hormone receptor Proteins 0.000 description 7
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- VWPRUVYOXHTRNX-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)oxyphenyl]methanamine Chemical compound C1CN(C)CCC1OC1=CC=CC(CN)=C1 VWPRUVYOXHTRNX-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 208000019022 Mood disease Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 238000000159 protein binding assay Methods 0.000 description 5
- BMALOIVINFWENC-UHFFFAOYSA-N 4-bromo-n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]benzamide;hydrochloride Chemical compound Cl.C1CN(C)CCC1OC1=CC=CC(CNC(=O)C=2C=CC(Br)=CC=2)=C1 BMALOIVINFWENC-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 3
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 108091008039 hormone receptors Proteins 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000002287 radioligand Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- PDXLPKBHUBRBLM-UHFFFAOYSA-N 3-bromo-n-[[3-(1-methylpiperidin-4-yl)oxyphenyl]methyl]benzamide;hydrochloride Chemical compound Cl.C1CN(C)CCC1OC1=CC=CC(CNC(=O)C=2C=C(Br)C=CC=2)=C1 PDXLPKBHUBRBLM-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 101150106280 Mchr1 gene Proteins 0.000 description 2
- 108700036626 Melanin-concentrating hormone receptor 1 Proteins 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 2
- 206010029216 Nervousness Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000008484 agonism Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 230000003031 feeding effect Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- JVCPFNWIDQJUQD-UHFFFAOYSA-N n-methyl-1-[3-(1-methylpiperidin-4-yl)oxyphenyl]methanamine Chemical compound CNCC1=CC=CC(OC2CCN(C)CC2)=C1 JVCPFNWIDQJUQD-UHFFFAOYSA-N 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- BZMMRNKDONDVIB-UHFFFAOYSA-N (1-ethoxycyclopropyl)oxy-trimethylsilane Chemical compound CCOC1(O[Si](C)(C)C)CC1 BZMMRNKDONDVIB-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 1
- OLNGVOCJQJRMOV-UHFFFAOYSA-N 3-(1-methylpiperidin-4-yl)oxybenzaldehyde Chemical compound C1CN(C)CCC1OC1=CC=CC(C=O)=C1 OLNGVOCJQJRMOV-UHFFFAOYSA-N 0.000 description 1
- GTOREZKNVQACQD-UHFFFAOYSA-N 3-(1-methylpiperidin-4-yl)oxybenzonitrile Chemical compound C1CN(C)CCC1OC1=CC=CC(C#N)=C1 GTOREZKNVQACQD-UHFFFAOYSA-N 0.000 description 1
- RSDWWFMQBYZJIK-UHFFFAOYSA-N 3-(1-methylpiperidin-4-yl)oxybenzonitrile;hydrochloride Chemical compound Cl.C1CN(C)CCC1OC1=CC=CC(C#N)=C1 RSDWWFMQBYZJIK-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- JZTPKAROPNTQQV-UHFFFAOYSA-N 3-fluorobenzonitrile Chemical compound FC1=CC=CC(C#N)=C1 JZTPKAROPNTQQV-UHFFFAOYSA-N 0.000 description 1
- HGZJJKZPPMFIBU-UHFFFAOYSA-N 3-formylbenzonitrile Chemical compound O=CC1=CC=CC(C#N)=C1 HGZJJKZPPMFIBU-UHFFFAOYSA-N 0.000 description 1
- MRLGCTNJRREZHZ-UHFFFAOYSA-N 3-phenoxybenzaldehyde Chemical compound O=CC1=CC=CC(OC=2C=CC=CC=2)=C1 MRLGCTNJRREZHZ-UHFFFAOYSA-N 0.000 description 1
- BLGSETDWNUEFPJ-UHFFFAOYSA-N 4-benzylbenzoyl chloride Chemical compound C1=CC(C(=O)Cl)=CC=C1CC1=CC=CC=C1 BLGSETDWNUEFPJ-UHFFFAOYSA-N 0.000 description 1
- DENKGPBHLYFNGK-UHFFFAOYSA-N 4-bromobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Br)C=C1 DENKGPBHLYFNGK-UHFFFAOYSA-N 0.000 description 1
- RYAQFHLUEMJOMF-UHFFFAOYSA-N 4-phenoxybenzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1OC1=CC=CC=C1 RYAQFHLUEMJOMF-UHFFFAOYSA-N 0.000 description 1
- AOOZVQGGMFGGEE-UHFFFAOYSA-N 4-phenoxybenzoyl chloride Chemical compound C1=CC(C(=O)Cl)=CC=C1OC1=CC=CC=C1 AOOZVQGGMFGGEE-UHFFFAOYSA-N 0.000 description 1
- ICEKEZSKMGHZNT-UHFFFAOYSA-N 4-phenylmethoxybenzoyl chloride Chemical compound C1=CC(C(=O)Cl)=CC=C1OCC1=CC=CC=C1 ICEKEZSKMGHZNT-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101500028288 Homo sapiens Melanin-concentrating hormone Proteins 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 108050001286 Somatostatin Receptor Proteins 0.000 description 1
- 102000011096 Somatostatin receptor Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- WXPFMAQEOZAXFB-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)oxyphenyl]methanamine;hydrochloride Chemical compound Cl.C1CN(C)CCC1OC1=CC=CC(CN)=C1 WXPFMAQEOZAXFB-UHFFFAOYSA-N 0.000 description 1
- HUOFUOCSQCYFPW-UHFFFAOYSA-N [4-(trifluoromethoxy)phenyl]boronic acid Chemical compound OB(O)C1=CC=C(OC(F)(F)F)C=C1 HUOFUOCSQCYFPW-UHFFFAOYSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000008503 anti depressant like effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940054066 benzamide antipsychotics Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- XMLNCADGRIEXPK-KUMOIWDRSA-M chembl2146143 Chemical compound [Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N+]2(C)C)C(=O)C(CO)C1=CC=CC=C1 XMLNCADGRIEXPK-KUMOIWDRSA-M 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000003683 electrophilic halogenation reaction Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000019439 energy homeostasis Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000004634 feeding behavior Effects 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 102000034345 heterotrimeric G proteins Human genes 0.000 description 1
- 108091006093 heterotrimeric G proteins Proteins 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000008019 pharmaceutical lubricant Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003653 radioligand binding assay Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/03—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68583205P | 2005-05-31 | 2005-05-31 | |
| US60/685,832 | 2005-05-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20080011677A true KR20080011677A (ko) | 2008-02-05 |
Family
ID=37481914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020077027793A Withdrawn KR20080011677A (ko) | 2005-05-31 | 2006-05-29 | 신규 ｍｃｈｒ1 길항제 및 그의 ｍｃｈｒ1 매개된 상태 및장애의 치료를 위한 용도 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20080269275A1 (enExample) |
| EP (1) | EP1891065A4 (enExample) |
| JP (1) | JP2008542365A (enExample) |
| KR (1) | KR20080011677A (enExample) |
| CN (1) | CN101184753A (enExample) |
| AU (1) | AU2006253049B2 (enExample) |
| BR (1) | BRPI0610907A2 (enExample) |
| CA (1) | CA2610671A1 (enExample) |
| IL (1) | IL187248A0 (enExample) |
| MX (1) | MX2007014464A (enExample) |
| NO (1) | NO20076695L (enExample) |
| WO (1) | WO2006130075A1 (enExample) |
| ZA (1) | ZA200709922B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200730474A (en) | 2005-12-29 | 2007-08-16 | Schering Ag | Diamine derivatives as inhibitors of leukotriene A4 hydrolease |
| EP1973905A4 (en) * | 2006-01-06 | 2010-12-08 | Astrazeneca Ab | COMPOUNDS |
| AU2007283113A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use |
| US8470841B2 (en) | 2008-07-09 | 2013-06-25 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| SA110310332B1 (ar) | 2009-05-01 | 2013-12-10 | Astrazeneca Ab | مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل ) |
| JP2013503135A (ja) | 2009-08-26 | 2013-01-31 | サノフイ | 新規な結晶性複素芳香族フルオログリコシド水和物、その化合物を含んでなる医薬及びその使用 |
| AU2011275547B2 (en) | 2010-07-06 | 2015-10-29 | Astrazeneca Ab | Therapeutic agents 976 |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| UY34194A (es) | 2011-07-15 | 2013-02-28 | Astrazeneca Ab | ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad? |
| JP6562898B2 (ja) * | 2013-03-14 | 2019-08-21 | セルタクシス，インコーポレイテッド | ロイコトリエンａ４加水分解酵素の阻害剤 |
| AU2014240042C1 (en) | 2013-03-14 | 2019-09-05 | Celltaxis, Llc | Inhibitors of leukotriene A4 hydrolase |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH377826A (de) * | 1959-08-28 | 1964-05-31 | Geigy Ag J R | Verfahren zur Herstellung von neuen N-heterocyclischen Verbindungen |
| CH377824A (de) * | 1959-08-28 | 1964-05-31 | Geigy Ag J R | Verfahren zur Herstellung von neuen N-heterocyclischen Verbindungen |
| ZA829150B (en) * | 1981-12-14 | 1984-07-25 | American Home Prod | Benzo-fused heterocyclic compounds |
| IL69392A (en) * | 1982-08-13 | 1987-01-30 | Sanofi Sa | N-oxide nicotinamide derivatives,their preparation and pharmaceutical compositions containing them |
| FR2531704B1 (fr) * | 1982-08-13 | 1985-08-09 | Sanofi Sa | Amides d'acides (hetero)aromatiques n-substitues, leurs sels, procede pour leur preparation et compositions pharmaceutiques en contenant |
| JP2002003370A (ja) * | 1999-09-20 | 2002-01-09 | Takeda Chem Ind Ltd | メラニン凝集ホルモン拮抗剤 |
| US7115750B1 (en) * | 1999-09-20 | 2006-10-03 | Takeda Pharmaceutical Company Limited | Melanin concentrating hormone antagonist |
| MXPA03005744A (es) * | 2000-12-22 | 2003-09-05 | Schering Corp | Antagonistas de piperidina mch y su uso en el tratamiento de obesidad. |
| GB0124931D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| EP1501514B1 (en) * | 2002-05-03 | 2012-12-19 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| EP1593667A4 (en) * | 2003-02-12 | 2009-03-04 | Takeda Pharmaceutical | Amine derivative |
| US20080161344A1 (en) * | 2004-02-09 | 2008-07-03 | Steenstra Cheryl K | Melanin Concentrating Hormone Receptor Ligands: Substituted Tetrahydroisoquinoline Analogues |
-
2006
- 2006-05-29 CN CNA2006800191464A patent/CN101184753A/zh active Pending
- 2006-05-29 CA CA002610671A patent/CA2610671A1/en not_active Abandoned
- 2006-05-29 JP JP2008514586A patent/JP2008542365A/ja active Pending
- 2006-05-29 AU AU2006253049A patent/AU2006253049B2/en not_active Ceased
- 2006-05-29 EP EP06747815A patent/EP1891065A4/en not_active Withdrawn
- 2006-05-29 US US11/914,400 patent/US20080269275A1/en not_active Abandoned
- 2006-05-29 MX MX2007014464A patent/MX2007014464A/es not_active Application Discontinuation
- 2006-05-29 WO PCT/SE2006/000621 patent/WO2006130075A1/en not_active Ceased
- 2006-05-29 BR BRPI0610907-1A patent/BRPI0610907A2/pt not_active IP Right Cessation
- 2006-05-29 KR KR1020077027793A patent/KR20080011677A/ko not_active Withdrawn
-
2007
- 2007-11-08 IL IL187248A patent/IL187248A0/en unknown
- 2007-11-16 ZA ZA200709922A patent/ZA200709922B/xx unknown
- 2007-12-28 NO NO20076695A patent/NO20076695L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2610671A1 (en) | 2006-12-07 |
| NO20076695L (no) | 2008-02-28 |
| WO2006130075A1 (en) | 2006-12-07 |
| BRPI0610907A2 (pt) | 2008-12-02 |
| AU2006253049B2 (en) | 2010-05-27 |
| ZA200709922B (en) | 2008-11-26 |
| IL187248A0 (en) | 2008-02-09 |
| AU2006253049A1 (en) | 2006-12-07 |
| US20080269275A1 (en) | 2008-10-30 |
| JP2008542365A (ja) | 2008-11-27 |
| CN101184753A (zh) | 2008-05-21 |
| EP1891065A4 (en) | 2010-07-28 |
| MX2007014464A (es) | 2008-02-07 |
| EP1891065A1 (en) | 2008-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1838677B1 (en) | Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride | |
| JP4488891B2 (ja) | Ｎ−［フェニル（ピペリジン−２−イル）メチル］ベンズアミド誘導体、その製造法、およびその治療用途 | |
| KR20080011677A (ko) | 신규 ｍｃｈｒ1 길항제 및 그의 ｍｃｈｒ1 매개된 상태 및장애의 치료를 위한 용도 | |
| US20070293529A1 (en) | Tetrasubstituted ureas as modulators of 11-beta hydroxyl steroid dehydrogenase type 1 | |
| US20020035113A1 (en) | Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use | |
| EP0287339B1 (en) | Piperidine opioid antagonists | |
| CA2621255A1 (en) | Amido compounds and their use as pharmaceuticals | |
| SK283425B6 (sk) | Deriváty 8-azabicyklo[3,2,1]okt-2-énu, spôsob ich prípravy a použitia | |
| WO2007099423A1 (en) | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists | |
| BG100040A (bg) | Индолови производни като 5-нт1а и/или 5-нт2 лиганди | |
| SK188399A3 (en) | Substituted 1,2,3,4-tetrahydronaphthalene derivatives | |
| CN1481360A (zh) | 蕈毒碱拮抗剂 | |
| WO2004052371A2 (en) | Cyclic quinoline compounds for use in mch receptor related disorders | |
| KR19990064111A (ko) | 신경전달물질 재흡수 저해제인 융합구조의 트로판 유도체 | |
| CN102056898A (zh) | 作为阳性变构调节剂的酰胺衍生物和其使用方法 | |
| CZ657890A3 (cs) | Chromanový derivát, způsob jeho výroby a farmaceutický prostředek s jeho obsahem | |
| JP2008523075A (ja) | ５ｈｔ２ｃレセプター関連障害の処置に有用な５ｈｔ２ｃレセプターのモジュレーターとしてのｎ−ビアリールピペラジン誘導体およびｎ−アリールヘテロアリールピペラジン誘導体 | |
| KR20170129906A (ko) | 유기 화합물 | |
| JP2009526844A (ja) | ピペラジン誘導体 | |
| MXPA06015267A (es) | Antagonistas diazabiciclicos del receptor histamina-3. | |
| JP3786983B2 (ja) | ピロリジノン誘導体 | |
| JP2009522354A (ja) | 化合物 | |
| JP3786984B2 (ja) | ピペラジン誘導体 | |
| CN120957970A (zh) | 碳环苯基吡咯烷酮脲fpr2激动剂 | |
| JP2022505081A (ja) | ４－ピリジニルメチル－モルホリン誘導体および医薬としてのその使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20071129 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |